Bli medlem
Bli medlem

Du är här

2016-03-04

Cantargia AB: Cantargia Year-end report January - December 2015

Cantargia AB ("Cantargia") Year-end report for January - December 2015
is available on the company web-site (www.cantargia.com). An extract
from the report is presented below.

Significant events in the fourth quarter

· European Patent Office (EPO) issued an officially approved patent
for IL1RAP as target molecule for antibody therapy and leukemia
diagnostics.

· EPO had issued an intention to grant for the Company's application
concerning IL1RAP as a target molecule for antibody therapy and
diagnostics of several types of solid tumours.

· David Liberg took up the position as Vice President Cancer
Research.

· Selection of primary indications - non-small cell lung cancer and
pancreatic cancer.

· Data from the first toxicity study had been obtained and showed no
indications of toxicity in clinically relevant doses.

· Warrants of series 2010:1 were exercised, resulting in a dilution
of around 0.8 per cent for existing shareholders.

Significant events after the end of the period

· Approval from EPO of the patent application concerning IL1RAP as a
target molecule for antibody therapy and diagnostics of several types
of solid tumours.

· Approval in Australia for the patent application to use IL1RAP as
target molecule for antibody treatment of haematological cancer
diseases.

Financial information

Twelve months (1 Jan 2015 - 31 Dec 2015)

· Other operating revenue was KSEK 0 (0).
· Earnings after financial items were KSEK -17,190 (-8,370).
· Earnings per share were approximately SEK -1.27 (-0.62).
· The equity/assets ratio was approximately 89 (20) per cent.

Fourth quarter (1 Oct 2015 - 31 Dec 2015)

· Other operating revenue was KSEK 0 (0).
· Earnings after financial items were KSEK -5,003 (-2,547).
· Earnings per share were approximately SEK -0.37 (-0.19).

Definitions

Earnings per share: Profit for the period divided by 13,505,874 shares
as of 31 December 2015.

Equity/assets ratio: Equity divided by total capital.
Figures in parentheses refer to the same period in the previous year.
The Interim report 1, for January - March 2016 will be presented May
16, 2016. Previously announced date was May 11, 2016.

For further information, please contact

Göran Forsberg, CEO
Telephone: +46 (0)46-275 62 60
E-mail: goran.forsberg@cantargia.com

-----------------------------------------------------------
http://news.cision.com/cantargia-ab/r/cantargia-year-end-report-january-...
http://mb.cision.com/Main/7470/9926908/483547.pdf

Författare WKR

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.